Discover how cutting-edge technology used in COVID-19 vaccines is now showing promise in fighting the deadly Clostridioides difficile infection. This intestinal bug, responsible for 30,000 deaths annually in the US, has been a challenge due to limited treatment options and lack of approved vaccines.
After antibiotics disrupt healthy gut bacteria, C. difficile can wreak havoc by causing symptoms ranging from mild diarrhea to life-threatening sepsis. Traditional vaccine attempts have fallen short, but a new mRNA vaccine developed by researchers at the University of Pennsylvania is changing the game.
This innovative vaccine targets multiple proteins crucial for C. difficile’s disease-causing abilities. In animal studies, including mice and hamsters, this mRNA vaccine triggered a robust immune response involving antibodies, immunoglobulins, and T cells – providing broad protection against infection.
The results speak for themselves: all vaccinated mice survived exposure to a lethal dose of C. difficile while unvaccinated mice succumbed within days. Even when infected post-vaccination, mice showed mild symptoms and quick recovery. The immune defense lasted long-term too; vaccinated mice challenged with a second infection six months later fared just as well as they did initially.
2024-10-03 13:00:00
Read more at www.sciencenews.org